These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 34376537)

  • 1. Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming.
    Simonetta F; Lohmeyer JK; Hirai T; Maas-Bauer K; Alvarez M; Wenokur AS; Baker J; Aalipour A; Ji X; Haile S; Mackall CL; Negrin RS
    Clin Cancer Res; 2021 Nov; 27(21):6054-6064. PubMed ID: 34376537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Harnessing Chimeric Antigen Receptor-engineered Invariant Natural Killer T Cells: Therapeutic Strategies for Cancer and the Tumor Microenvironment.
    Wang Y; Li YR
    Curr Pharm Biotechnol; 2024; 25(15):2001-2011. PubMed ID: 38310449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy.
    Li YR; Zhou Y; Kim YJ; Zhu Y; Ma F; Yu J; Wang YC; Chen X; Li Z; Zeng S; Wang X; Lee D; Ku J; Tsao T; Hardoy C; Huang J; Cheng D; Montel-Hagen A; Seet CS; Crooks GM; Larson SM; Sasine JP; Wang X; Pellegrini M; Ribas A; Kohn DB; Witte O; Wang P; Yang L
    Cell Rep Med; 2021 Nov; 2(11):100449. PubMed ID: 34841295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Traversing the bench to bedside journey for iNKT cell therapies.
    O'Neal J; Mavers M; Jayasinghe RG; DiPersio JF
    Front Immunol; 2024; 15():1436968. PubMed ID: 39170618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy.
    Li YR; Zhou Y; Yu J; Zhu Y; Lee D; Zhu E; Li Z; Kim YJ; Zhou K; Fang Y; Lyu Z; Chen Y; Tian Y; Huang J; Cen X; Husman T; Cho JM; Hsiai T; Zhou JJ; Wang P; Puliafito BR; Larson SM; Yang L
    Mol Ther; 2024 Jun; 32(6):1849-1874. PubMed ID: 38584391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential alternatives to αβ-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review.
    Tang C; Zhang Y
    Pathol Res Pract; 2024 Oct; 262():155518. PubMed ID: 39146830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity.
    Moraes Ribeiro E; Secker KA; Nitulescu AM; Schairer R; Keppeler H; Wesle A; Schmid H; Schmitt A; Neuber B; Chmiest D; Podavini S; Märklin M; Klimovich B; Schmitt M; Korkmaz F; Lengerke C; Schneidawind C; Schneidawind D
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38296597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.
    Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K
    Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative assessment of autologous and allogeneic iNKT cell transfer in iNKT cell-based immunotherapy.
    Takami M; Motohashi S
    Front Immunol; 2024; 15():1457771. PubMed ID: 39224603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
    Marcus A; Eshhar Z
    Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of allogeneic CAR T-cells].
    Alcazer V; Depil S
    Bull Cancer; 2021 Oct; 108(10S):S73-S80. PubMed ID: 34920810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Third-party CD4+ invariant natural killer T cells protect from murine GVHD lethality.
    Schneidawind D; Baker J; Pierini A; Buechele C; Luong RH; Meyer EH; Negrin RS
    Blood; 2015 May; 125(22):3491-500. PubMed ID: 25795920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. invariant Natural Killer T cell therapy as a novel therapeutic approach in hematological malignancies.
    Boonchalermvichian C; Yan H; Gupta B; Rubin A; Baker J; Negrin RS
    Front Transplant; 2024; 3():1353803. PubMed ID: 38993780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invariant natural killer T-cell subsets have diverse graft-versus-host-disease-preventing and antitumor effects.
    Maas-Bauer K; Lohmeyer JK; Hirai T; Ramos TL; Fazal FM; Litzenburger UM; Yost KE; Ribado JV; Kambham N; Wenokur AS; Lin PY; Alvarez M; Mavers M; Baker J; Bhatt AS; Chang HY; Simonetta F; Negrin RS
    Blood; 2021 Sep; 138(10):858-870. PubMed ID: 34036317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma.
    Verneris MR; Ito M; Baker J; Arshi A; Negrin RS; Shizuru JA
    Biol Blood Marrow Transplant; 2001; 7(10):532-42. PubMed ID: 11760085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities.
    Vasic D; Lee JB; Leung Y; Khatri I; Na Y; Abate-Daga D; Zhang L
    Sci Immunol; 2022 Apr; 7(70):eabl3642. PubMed ID: 35452255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses.
    Choi DH; Kim KS; Yang SH; Chung DH; Song B; Sprent J; Cho JH; Sung YC
    Cancer Res; 2011 Dec; 71(24):7442-51. PubMed ID: 22028323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering Tolerance toward Allogeneic CAR-T Cells by Regulation of MHC Surface Expression with Human Herpes Virus-8 Proteins.
    Wang X; Cabrera FG; Sharp KL; Spencer DM; Foster AE; Bayle JH
    Mol Ther; 2021 Feb; 29(2):718-733. PubMed ID: 33554868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.